JP2018501247A5 - - Google Patents

Download PDF

Info

Publication number
JP2018501247A5
JP2018501247A5 JP2017533220A JP2017533220A JP2018501247A5 JP 2018501247 A5 JP2018501247 A5 JP 2018501247A5 JP 2017533220 A JP2017533220 A JP 2017533220A JP 2017533220 A JP2017533220 A JP 2017533220A JP 2018501247 A5 JP2018501247 A5 JP 2018501247A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
antibody
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501247A (ja
JP6649953B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/066400 external-priority patent/WO2016100679A1/en
Publication of JP2018501247A publication Critical patent/JP2018501247A/ja
Publication of JP2018501247A5 publication Critical patent/JP2018501247A5/ja
Application granted granted Critical
Publication of JP6649953B2 publication Critical patent/JP6649953B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533220A 2014-12-19 2015-12-17 免疫療法による治療および組成物 Expired - Fee Related JP6649953B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094944P 2014-12-19 2014-12-19
US62/094,944 2014-12-19
PCT/US2015/066400 WO2016100679A1 (en) 2014-12-19 2015-12-17 Immunotherapy treatments and compositions

Publications (3)

Publication Number Publication Date
JP2018501247A JP2018501247A (ja) 2018-01-18
JP2018501247A5 true JP2018501247A5 (https=) 2019-01-10
JP6649953B2 JP6649953B2 (ja) 2020-02-19

Family

ID=56127600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533220A Expired - Fee Related JP6649953B2 (ja) 2014-12-19 2015-12-17 免疫療法による治療および組成物

Country Status (8)

Country Link
US (1) US10624965B2 (https=)
EP (1) EP3233104B1 (https=)
JP (1) JP6649953B2 (https=)
AU (1) AU2015364559B2 (https=)
CA (1) CA2971471C (https=)
DK (1) DK3233104T3 (https=)
ES (1) ES2781673T3 (https=)
WO (1) WO2016100679A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039132A1 (en) * 2016-08-24 2018-03-01 Wisconsin Alumni Research Foundation Methods and compositions for the treatment of cancer
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides
JP2023536815A (ja) * 2020-07-28 2023-08-30 スサヴィオン バイオサイエンシーズ インコーポレイテッド 好中球駆動性炎症性病変の治療方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034773B2 (en) * 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
US7838497B2 (en) * 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA3017298C (en) * 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
WO2013096829A2 (en) 2011-12-22 2013-06-27 Arizona Biomedical Research Commission Activation of cellular assault processes in the treatment of glioblastoma multiforme
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9381244B2 (en) * 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer

Similar Documents

Publication Publication Date Title
Kudarha et al. Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches
Butowski et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
Brunsvig et al. Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer
JP2016530323A5 (https=)
RU2016148645A (ru) Антитела к в7-н1 и к ctlа-4 для лечения немелкоклеточного рака легкого
Sayour et al. Manipulation of innate and adaptive immunity through cancer vaccines
RU2018105985A (ru) Новый подход к лечению рака с применением иммуномодуляции
JP2019504892A5 (https=)
IL292193B2 (en) Anti-b7-h1 antibodies for treating tumors
JP7780444B2 (ja) ＩＦＮ－γの抗腫瘍補助薬の調製への応用
JP2017506662A5 (https=)
CN108392633A (zh) Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用
Li et al. Boosting CAR-T cell therapy through vaccine synergy
FI3463345T3 (fi) Farmaseuttisia yhdistelmiä
CN106540256A (zh) 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
EP3371210B1 (en) Combination therapy for malignant diseases
WO2015131176A1 (en) Compositions, methods, and kits for treatment of cancer
Wang et al. A dual-STING-activating nanosystem expands cancer immunotherapeutic temporal window
Skalickova et al. Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer
JP2018501247A5 (https=)
US20160340650A1 (en) Blood derived immune stimulatory compositions
Liu et al. Cancer biotherapy: review and prospect
CN109674788B (zh) 羧胺三唑与ido1抑制剂组合在抗肿瘤中的用途
Young et al. Ideal timing of immunotherapy with radiation in murine tumor models
Liu et al. The enhanced cancer nanovaccine by bidirectionally blocking CXCL12/CXCR4 axis to inhibit the recurrence and metastasis of triple-negative breast cancer